143 related articles for article (PubMed ID: 29719053)
1. IgG4 anti-infliximab in treated patients: Clinical impact and temporal evolution.
Vultaggio A; Nencini F; Carraresi A; Pratesi S; Movérare R; Eriksson C; Venemalm L; Maggi E; Matucci A
Allergy; 2018 Nov; 73(11):2172-2181. PubMed ID: 29719053
[TBL] [Abstract][Full Text] [Related]
2. Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactions.
Vultaggio A; Petroni G; Pratesi S; Nencini F; Cammelli D; Milla M; Prignano F; Annese V; Romagnani S; Maggi E; Matucci A;
Clin Exp Immunol; 2016 Dec; 186(3):364-372. PubMed ID: 27569750
[TBL] [Abstract][Full Text] [Related]
3. The Kinetics of Antidrug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immune-Mediated Disorders.
Nencini F; Vultaggio A; Pratesi S; Cammelli D; Milla M; Fiori G; Bagnoli S; Prignano F; Romagnani S; Maggi E; Matucci A
J Allergy Clin Immunol Pract; 2018; 6(6):2065-2072.e2. PubMed ID: 29660428
[TBL] [Abstract][Full Text] [Related]
4. IgE antibodies and skin tests in immediate hypersensitivity reactions to infliximab in inflammatory bowel disease: impact on infliximab retreatment.
Fréling E; Peyrin-Biroulet L; Poreaux C; Morali A; Waton J; Schmutz JL; Guéant JL; Barbaud A
Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1200-8. PubMed ID: 26181108
[TBL] [Abstract][Full Text] [Related]
5. Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab.
Matucci A; Pratesi S; Petroni G; Nencini F; Virgili G; Milla M; Maggi E; Vultaggio A
Clin Exp Allergy; 2013 Jun; 43(6):659-64. PubMed ID: 23711128
[TBL] [Abstract][Full Text] [Related]
6. Detection of anti-infliximab antibodies is impacted by antibody titer, infliximab level and IgG4 antibodies: a systematic comparison of three different assays.
Afonso J; Lopes S; Gonçalves R; Caldeira P; Lago P; Tavares de Sousa H; Ramos J; Gonçalves AR; Ministro P; Rosa I; Vieira AI; Coelho R; Tavares P; Soares J; Sousa AL; Carvalho D; Sousa P; da Silva JP; Meira T; Silva Ferreira F; Dias CC; Chowers Y; Ben-Horin S; Magro F;
Therap Adv Gastroenterol; 2016 Nov; 9(6):781-794. PubMed ID: 27803733
[TBL] [Abstract][Full Text] [Related]
7. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.
Moots RJ; Xavier RM; Mok CC; Rahman MU; Tsai WC; Al-Maini MH; Pavelka K; Mahgoub E; Kotak S; Korth-Bradley J; Pedersen R; Mele L; Shen Q; Vlahos B
PLoS One; 2017; 12(4):e0175207. PubMed ID: 28448562
[TBL] [Abstract][Full Text] [Related]
8. Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies.
Kopylov U; Mazor Y; Yavzori M; Fudim E; Katz L; Coscas D; Picard O; Chowers Y; Eliakim R; Ben-Horin S
Inflamm Bowel Dis; 2012 Sep; 18(9):1628-33. PubMed ID: 22038899
[TBL] [Abstract][Full Text] [Related]
9. Antidrug antibodies against TNF-blocking agents: correlations between disease activity, hypersensitivity reactions, and different classes of immunoglobulins.
Benucci M; Li Gobbi F; Meacci F; Manfredi M; Infantino M; Severino M; Testi S; Sarzi-Puttini P; Ricci C; Atzeni F
Biologics; 2015; 9():7-12. PubMed ID: 25733803
[TBL] [Abstract][Full Text] [Related]
10. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease.
Steenholdt C; Bendtzen K; Brynskov J; Thomsen OØ; Munck LK; Christensen LA; Pedersen G; Kjeldsen J; Ainsworth MA
J Crohns Colitis; 2015 Mar; 9(3):238-45. PubMed ID: 25576753
[TBL] [Abstract][Full Text] [Related]
11. Association of female sex and positive rheumatoid factor with low serum infliximab and anti-drug antibodies, related to treatment failure in early rheumatoid arthritis: results from the SWEFOT trial population.
Hambardzumyan K; Hermanrud C; Marits P; Vivar N; Ernestam S; Wallman JK; van Vollenhoven RF; Fogdell-Hahn A; Saevarsdottir S;
Scand J Rheumatol; 2019 Sep; 48(5):362-366. PubMed ID: 31244356
[No Abstract] [Full Text] [Related]
12. Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?
Murdaca G; Spanò F; Contatore M; Guastalla A; Penza E; Magnani O; Puppo F
Expert Opin Drug Saf; 2016 Jan; 15(1):43-52. PubMed ID: 26559805
[TBL] [Abstract][Full Text] [Related]
13. Discrimination of Anti-drug Antibodies With Neutralizing Capacity in Infliximab- and Adalimumab-Treated Patients: Comparison of the Homogeneous Mobility Shift Assay and the Affinity Capture and Elution Assay.
Hock BD; McKenzie JL; Goddard L; Smith SM; McEntyre CJ; Keating PE
Ther Drug Monit; 2018 Dec; 40(6):705-715. PubMed ID: 30439789
[TBL] [Abstract][Full Text] [Related]
14. Anti-infliximab Antibodies with Neutralizing Capacity in Patients with Inflammatory Bowel Disease: Distinct Clinical Implications Revealed by a Novel Assay.
Weisshof R; Ungar B; Blatt A; Dahan A; Pressman S; Waterman M; Kopylov U; Ben-Horin S; Chowers Y
Inflamm Bowel Dis; 2016 Jul; 22(7):1655-61. PubMed ID: 27120567
[TBL] [Abstract][Full Text] [Related]
15. Early monitoring of anti-infliximab antibodies by drug-tolerant assay predicts later immunogenicity and drug survival in rheumatic diseases.
Martínez-Feito A; Novella-Navarro M; Hernández-Breijo B; Nozal P; Peiteado D; Villalba A; Nuño L; Monjo I; Pascual-Salcedo D; Balsa A; Plasencia-Rodríguez C
Rheumatology (Oxford); 2024 Jan; ():. PubMed ID: 38175741
[TBL] [Abstract][Full Text] [Related]
16. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions.
Vultaggio A; Matucci A; Nencini F; Pratesi S; Parronchi P; Rossi O; Romagnani S; Maggi E
Allergy; 2010 May; 65(5):657-61. PubMed ID: 19951375
[TBL] [Abstract][Full Text] [Related]
17. Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays.
Van Stappen T; Brouwers E; Tops S; Geukens N; Vermeire S; Declerck PJ; Gils A
Ther Drug Monit; 2015 Aug; 37(4):479-85. PubMed ID: 25525757
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of Infliximab Among Patients With Behçet Syndrome: A Controlled Study.
Esatoglu SN; Akkoc-Mustafayev FN; Ozguler Y; Ozbakır F; Nohut OK; Cevirgen D; Hamuryudan V; Hatemi I; Celik AF; Yazici H; Hatemi G
Front Immunol; 2020; 11():618973. PubMed ID: 33414791
[TBL] [Abstract][Full Text] [Related]
19. Surface plasmon resonance assays for the therapeutic drug monitoring of infliximab indicate clinical relevance of anti-infliximab antibody binding properties.
Grasmeier MK; Weber S; Treiber M; Thaler MA; Luppa PB
Clin Chem Lab Med; 2023 Jun; 61(7):1255-1265. PubMed ID: 36753693
[TBL] [Abstract][Full Text] [Related]
20. Infusion reactions during infliximab treatment are not associated with IgE anti-infliximab antibodies.
van Schie KA; Ooijevaar-De Heer P; Kruithof S; Plasencia C; Jurado T; Pascual Salcedo D; Brandse JF; d'Haens GR; Wolbink GJ; Rispens T
Ann Rheum Dis; 2017 Jul; 76(7):1285-1288. PubMed ID: 28455438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
